Listed as number three in pharma sales, GlaxoSmithKline has had some rough luck thanks in part to the diabetes drug Avandia, which has been pulled out of Europe and restricted in the U.S after global side effect concerns since 2007. The company cut its losses on the drug, writing off $233 million in supplies and eliminating its marketing efforts of the drug.

The company has racked up some charges against its earnings, including over $6 billion in the fourth quarter of 2010 from Avandia and marketing settlements. GSK settled 10,000 Avandia lawsuits for a combined $460 million. Also, the company hit number three on FiercePharma's Top Layoffs of 2010 list with 5,201 jobs lost. While other companies look towards more spinoffs, GSK has focused on emerging markets as its ticket to higher revenue. It purchased Laboratorios Phoenix in 2009 and China's MeiRui in 2010; the UK-based company said the impact of its layoffs would be masked by more job opportunities in Asia and South America.

In early 2011, GSK and Human Genome Sciences gained FDA approval for Benlysta, the first new lupus treatment in more than 50 years, and experts believe it could be a $3 billion to $5 billion worldwide sales heyday for the partnership. But the FDA denied an extended approval and a potential $1 billion in sales to GSK from the prostate drug Avodart. While the drug was effective against low-risk malignant tumors, it potentially heightened the risk of developing more aggressive tumors.

GSK spun off its HIV treatments into ViiV Healthcare in 2009, combining it with Pfizer's former R&D efforts in the field. ViiV markets Ziagen, Trizivir, Epzicom and abacavir as part of its suite of drugs for HIV/AIDS.



Latest Headlines

Latest Headlines

GSK delays Japanese hair-loss treatment launch on Catalent plant problems

Suspected product tampering has put production at a French Catalent plant on hold--and GlaxoSmithKline is paying the price. The British pharma giant has delayed the launch of hair-loss drug Zagallo in Japan while it searches for another manufacturing site.

GSK delays Japanese drug launch after Catalent closes plant to investigate tampering

Catalent's production interruption at a French plant because of suspected product tampering is being felt by clients. GlaxoSmithKline has had to delay the launch of a hair loss drug in Japan while it figures out another location that can produce it.

GlaxoSmithKline partners with fast-growing Zymeworks in $440M-plus deal

Vancouver-based Zymeworks has added another marquee collaboration to its growing list of development partnerships.

Study finds no shortage of misleading HPV vaccine websites

Research published by the Journal of Adolescent Health demonstrates a reality that Big Pharmas Merck and GlaxoSmithKline have experienced for years: there's an abundance of misinformation regarding HPV vaccines.

GSK jumps on the 'smart inhaler' bandwagon with Ellipta sensor deal

The more researchers know about patient adherence to drugs, the better they can adapt products to keep patients compliant--which, in turn, helps pad sales. Makers of respiratory drugs have picked up on that lately, and now, GlaxoSmithKline is the latest to forge an adherence-minded technology deal.

Parents may be misled by inaccurate HPV vaccine websites, report says

A new study published in the Journal of Adolescent Health found that parents looking online for information about HPV vaccines can be misled by websites containing inaccurate or incomplete medical information, Reuters reported.

GSK, Propeller Health partner to study smart inhalers for asthma, COPD drugs

Fierce 15 company Propeller Health has announced an R&D collaboration with GlaxoSmithKline, under which it will design and manufacture a custom sensor for the Ellipta inhaler to be used in GSK clinical studies of asthma and COPD.

Are Glaxo's China sales reforms putting it at a commercial disadvantage?

Since Chinese officials slapped GlaxoSmithKline with a $489 million fine on bribery charges, the company has overhauled its sales practices to quash corruption there. But some in the industry say its reforms--which include eliminating sales-based compensation incentives for reps, nixing doctor speaking fees and tripling an in-house compliance team that checks every submitted receipt--could be negatively impacting its top line at a time when the company's already hurting. 

GSK's anticorruption overhaul in China may be hobbling sales

Since Chinese officials slapped GlaxoSmithKline with a $489 million fine on bribery charges, the company has overhauled its sales practices to quash corruption. But some say its reforms could hurt its top line at a time when the company's already suffering.

JAMA: Valeant's 18-fold price hikes top widespread increases in dermatology prices

A new study shows that prices for 19 brand-name dermatology meds, including two from Valeant Pharmaceuticals, have increased almost fivefold, on average, over the past 6 years.